siRNA 治疗药物的递送：障碍与载体。
Delivery of siRNA therapeutics: barriers and carriers.
机构信息
Optimum Therapeutics LLC, The Ohio State University Science Tech Village, Columbus, 43212, USA.
出版信息
AAPS J. 2010 Dec;12(4):492-503. doi: 10.1208/s12248-010-9210-4. Epub 2010 Jun 11.
Abstract
RNA interference is a naturally occurring endogenous regulatory process where short double-stranded RNA causes sequence-specific posttranscriptional gene silencing. Small interference RNA (siRNA) represents a promising therapeutic strategy. Clinical evaluations of siRNA therapeutics in locoregional treatment settings began in 2004. Systemic siRNA therapy is hampered by the barriers for siRNA to reach their intended targets in the cytoplasm and to exert their gene silencing activity. The three goals of this review were to provide an overview of (a) the barriers to siRNA delivery, from the perspectives of physicochemical properties of siRNA, pharmacokinetics and biodistribution, and intracellular trafficking; (b) the non-viral siRNA carriers including cell-penetrating peptides, polymers, dendrimers, siRNA bioconjugates, and lipid-based siRNA carriers; and (c) the current status of the clinical trials of siRNA therapeutics.
摘要
RNA 干扰是一种自然发生的内源性调节过程，其中短双链 RNA 导致序列特异性转录后基因沉默。小干扰 RNA（siRNA）代表了一种有前途的治疗策略。2004 年开始在局部治疗环境中对 siRNA 治疗进行临床评估。系统的 siRNA 治疗受到阻碍，因为 siRNA 难以到达细胞质中的靶标并发挥其基因沉默活性。本综述的三个目标是提供（a）siRNA 递送至靶细胞的障碍的概述，包括 siRNA 的理化性质、药代动力学和生物分布以及细胞内转运；（b）非病毒 siRNA 载体，包括穿透肽、聚合物、树枝状聚合物、siRNA 生物缀合物和基于脂质的 siRNA 载体；和（c）siRNA 治疗的临床试验的现状。
相似文献
1
Delivery of siRNA therapeutics: barriers and carriers.siRNA 治疗药物的递送：障碍与载体。
AAPS J. 2010 Dec;12(4):492-503. doi: 10.1208/s12248-010-9210-4. Epub 2010 Jun 11.
2
Supramolecular assemblies in functional siRNA delivery: where do we stand?功能性 siRNA 递送上的超分子组装：我们处于什么位置？
Biomaterials. 2012 Mar;33(8):2546-69. doi: 10.1016/j.biomaterials.2011.11.079. Epub 2011 Dec 30.
3
siRNA based drug design, quality, delivery and clinical translation.基于 siRNA 的药物设计、质量、传递和临床转化。
Nanomedicine. 2020 Oct;29:102239. doi: 10.1016/j.nano.2020.102239. Epub 2020 Jun 13.
4
siRNA therapeutics: a clinical reality.siRNA 疗法：临床现实。
Sci China Life Sci. 2020 Apr;63(4):485-500. doi: 10.1007/s11427-018-9438-y. Epub 2019 Apr 30.
5
Efficient and targeted delivery of siRNA in vivo.体内 siRNA 的高效和靶向递送。
FEBS J. 2010 Dec;277(23):4814-27. doi: 10.1111/j.1742-4658.2010.07904.x.
6
Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo.将小干扰RNA（siRNA）递送至靶细胞胞质：光化学内化促进内体逃逸并提高体内外沉默效率。
Curr Pharm Des. 2008;14(34):3686-97. doi: 10.2174/138161208786898789.
7
Polycation-based nanoparticle delivery for improved RNA interference therapeutics.基于聚阳离子的纳米颗粒递送用于改善RNA干扰疗法。
Expert Opin Biol Ther. 2007 Dec;7(12):1811-22. doi: 10.1517/14712598.7.12.1811.
8
PAMAM Dendrimers as a Delivery System for Small Interfering RNA.PAMAM 树枝状聚合物作为小干扰 RNA 的递送系统。
Methods Mol Biol. 2020;2115:91-106. doi: 10.1007/978-1-0716-0290-4_5.
9
Non-viral nanosystems for systemic siRNA delivery.用于系统性 siRNA 递送的非病毒纳米系统。
Pharmacol Res. 2010 Aug;62(2):100-14. doi: 10.1016/j.phrs.2009.11.013. Epub 2009 Dec 17.
10
A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.一种用于癌症治疗中有效基因沉默的双重靶向树枝状聚合物介导的 siRNA 传递系统。
J Am Chem Soc. 2018 Nov 28;140(47):16264-16274. doi: 10.1021/jacs.8b10021. Epub 2018 Nov 1.
引用本文的文献
1
Therapeutic Approaches of Viral Gene Silencing by Small Interfering RNA: Strategies to Prevent the Emergence of Antiviral Resistant Escape Mutants.小干扰RNA介导的病毒基因沉默治疗方法：预防抗病毒耐药逃逸突变体出现的策略
Pharmaceuticals (Basel). 2025 Jul 1;18(7):987. doi: 10.3390/ph18070987.
2
Intravenous Administration of sRNA Nanoparticles for Treatment of Osteoporosis in Mice.静脉注射sRNA纳米颗粒用于治疗小鼠骨质疏松症
Pharmaceutics. 2025 Jun 17;17(6):789. doi: 10.3390/pharmaceutics17060789.
3
Autologous platelet delivery of siRNAs by autologous plasma protein self-assembled nanoparticles for the treatment of acute kidney injury.通过自体血浆蛋白自组装纳米颗粒进行小干扰RNA的自体血小板递送用于治疗急性肾损伤。
J Nanobiotechnology. 2025 Mar 29;23(1):256. doi: 10.1186/s12951-025-03338-6.
4
Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.肺动脉高压：分子机制与临床研究
MedComm (2020). 2025 Mar 10;6(3):e70134. doi: 10.1002/mco2.70134. eCollection 2025 Mar.
5
Injured Cardiac Tissue-Targeted Delivery of TGFβ1 siRNA by FAP Aptamer-Functionalized Extracellular Vesicles Promotes Cardiac Repair.通过FAP适配体功能化细胞外囊泡实现对损伤心脏组织的靶向递送TGFβ1 siRNA可促进心脏修复。
Int J Nanomedicine. 2025 Mar 1;20:2575-2592. doi: 10.2147/IJN.S497428. eCollection 2025.
6
Multi-functional near-infrared fluorescent polymer dot-siRNA for gene expression regulation.用于基因表达调控的多功能近红外荧光聚合物点-小干扰RNA
J Mater Chem B. 2025 Feb 5;13(6):2124-2139. doi: 10.1039/d4tb01954g.
7
CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo.靶向FGFR3-TACC3融合基因的CRISPR-Cas13a在体内外抑制膀胱癌细胞增殖
Onco Targets Ther. 2024 Dec 18;17:1197-1207. doi: 10.2147/OTT.S492659. eCollection 2024.
8
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.抗乙型肝炎病毒的高级 siRNA 递呈：机制见解和最新进展。
J Nanobiotechnology. 2024 Nov 30;22(1):745. doi: 10.1186/s12951-024-03004-3.
9
Exploring the potential of nanomedicine for gene therapy across the physicochemical and cellular barriers.探索纳米医学跨越物理化学和细胞屏障用于基因治疗的潜力。
Funct Integr Genomics. 2024 Sep 28;24(5):177. doi: 10.1007/s10142-024-01459-z.
10
Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems-An Integrated Approach towards Anticancer Synergism and Targeted Delivery.通过将双药共包封到脂质体系统中来改善皮肤癌治疗——一种实现抗癌协同作用和靶向递送的综合方法
Pharmaceutics. 2024 Sep 12;16(9):1200. doi: 10.3390/pharmaceutics16091200.
本文引用的文献
1
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.经靶向纳米粒系统给药的 siRNA 在人体中 RNAi 的证据。
Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.
2
Cutaneous short-interfering RNA therapy.皮肤的小干扰 RNA 治疗。
Expert Opin Drug Deliv. 2009 Dec;6(12):1333-49. doi: 10.1517/17425240903304032.
3
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.优化的适体-小干扰RNA嵌合体的全身给药促进表达前列腺特异性膜抗原（PSMA）的肿瘤消退。
Nat Biotechnol. 2009 Sep;27(9):839-49. doi: 10.1038/nbt.1560. Epub 2009 Aug 23.
4
Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.表面工程靶向 PPI 树状聚合物用于高效细胞内和肿瘤内 siRNA 递送。
J Control Release. 2009 Dec 16;140(3):284-93. doi: 10.1016/j.jconrel.2009.06.019. Epub 2009 Jun 28.
5
Small silencing RNAs: state-of-the-art.小干扰RNA：最新进展
Adv Drug Deliv Rev. 2009 Jul 25;61(9):672-703. doi: 10.1016/j.addr.2009.05.002. Epub 2009 May 7.
6
siRNA delivery systems for cancer treatment.用于癌症治疗的小干扰RNA递送系统。
Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62. doi: 10.1016/j.addr.2009.04.018. Epub 2009 May 5.
7
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA.使用负载有小干扰RNA的可生物降解聚合物纳米颗粒进行阴道内基因沉默。
Nat Mater. 2009 Jun;8(6):526-33. doi: 10.1038/nmat2444. Epub 2009 May 3.
8
siRNA vs. shRNA: similarities and differences.小干扰RNA与短发夹RNA：异同点
Adv Drug Deliv Rev. 2009 Jul 25;61(9):746-59. doi: 10.1016/j.addr.2009.04.004. Epub 2009 Apr 20.
9
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.非病毒载体介导的RNA干扰：其基因沉默特性及实现基于RNA干扰的基因治疗的重要因素。
Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Epub 2009 Apr 20.
10
Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape.使用经修饰以实现内体逃逸的细胞穿透肽进行细胞内小干扰RNA递送。
Adv Drug Deliv Rev. 2009 Jul 25;61(9):704-9. doi: 10.1016/j.addr.2009.04.005. Epub 2009 Apr 19.
Zotero 插件